We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
49 own
46 watching
Current Price
$0.77
$-0.03
(-3.38%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
74.52M
52-Week High
5.27
52-Week Low
0.68
Average Volume
0.55M
Dividend Yield
--
P/E Ratio
--
Market Capitalization74.52M
52-Week High5.27
52-Week Low0.68
Average Volume0.55M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
10hours ago
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia PR Newswire LEXINGTON, Mass., Dec. 5, 2022 Curis to review results during conference call, featuring commentaryby Dr. Eric Winer, M.D...
PR Newswire
2 months ago
Curis Announces Date for the 2nd Annual VISTA Symposium Curis Announces Date for the 2nd Annual VISTA Symposium PR Newswire LEXINGTON, Mass., Sept. 19, 2022 Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON...
PR Newswire
3 months ago
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study PR Newswire LEXINGTON, Mass., Aug. 30, 2022 Curis working with clinical...
PR Newswire
3 months ago
Thinking about buying stock in Curis, bluebird bio, Nerdy, Sientra, or Aquestive Therapeutics? Thinking about buying stock in Curis, bluebird bio, Nerdy, Sientra, or Aquestive Therapeutics? PR Newswire NEW YORK, Aug. 18, 2022 NEW YORK, Aug. 18, 2022 /PRNewswire/ -- InvestorsObserverissues critical...
PR Newswire
5 months ago
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.77
$-0.03
(-3.38%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00